key: cord-0685991-r8do6rst authors: Su, Ning; Wiefels, Christiane; Klein, Ran; Zeng, Wanzhen; Abbaspour, Farzad title: Intensity of hypermetabolic axillary lymph nodes in oncologic patients in relation to timeline following COVID-19 vaccination date: 2022-01-20 journal: J Med Imaging Radiat Sci DOI: 10.1016/j.jmir.2022.01.004 sha: c6df2ed1a4d42db755809c16ef8e4f10949a24d9 doc_id: 685991 cord_uid: r8do6rst PURPOSE: : First discovered in Wuhan, China in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is a highly contagious and deadly novel virus that quickly wreaked havoc throughout the world. As mass vaccination are now underway worldwide, clinicians have started to encounter a new clinical entity, COVID-19 vaccine-associated axillary lymphadenopathy. This presents a unique challenge to medical imagers, particularly in oncologic patients. METHODS: : In this retrospective study, we assessed metabolic activity, size, and timeline of COVID-19 vaccine-associated axillary hypermetabolic lymph nodes in 202 oncologic patients post vaccination with 18-fluorodeoxyglucose positron emission tomography (18-FDG PET). RESULTS: : When present, COVID-19 vaccine-associated hypermetabolic lymph nodes demonstrate a mean maximum standard uptake value (SUV(max)) of 2.5 ± 0.3, and more common in younger patients. The metabolic activity is the most intense in the first two weeks post vaccination and diminishes over time. By approximately 5-6 weeks, only about half of the patients demonstrated appreciable, low grade uptake compared to background. CONCLUSION: : Based on our preliminary results, we would recommend correlation with a history and time of vaccination and routine use of a pre-study patient questionnaire to guide interpretation to prevent over-diagnosis of axillary nodal metastases and/or unnecessary work-up in oncologic patients. and time of vaccination and routine use of a pre-study patient questionnaire to guide interpretation to prevent over-diagnosis of axillary nodal metastases and/or unnecessary work-up in oncologic patients. As our world enters a new phase of COVID-19 pandemic with mass vaccination, an ever-increasing number of people, especially people with chronic conditions (including oncologic patients), received, or are soon to receive COVID-19 vaccines. As of July 1, 2021, over 2.95 billion vaccine doses have been administered worldwide [1] . Health Canada has approved five COVID-19 vaccines for human use under emergency authorization. Over 25 million Canadians (65.9% of the population) have received at least one dose, and over 7.3 million Canadians, or 19.3% of the population are fully vaccinated, with over 38.2 million doses administered [2] . Among those five vaccines, two messenger RNA (mRNA) vaccines, Pfizer-BioNTech (tozinameran) and Moderna (mRNA-1273 SARS-CoV-2) and a viral vector vaccine made by Oxford-AstraZeneca saw particularly rapid nationwide deployment. Vaccine-associated lymphadenopathy is a known clinical entity long before the current pandemic [3] . As COVID-19 vaccines are typically administered intramuscularly in the deltoid muscle, regional lymphadenopathy in the axilla has become an increasingly common clinical scenario, considering the sheer number of people who are either partially or fully vaccinated. This also presents a unique challenge to medical imagers, especially in patients with certain malignancy with a predilection to axillary nodal spread, such as breast cancer, lymphoma, and melanoma. Therefore, it is crucial for medical imagers to recognize this potential imaging pitfall as an incidental finding in oncologic settings, with consideration of the intensity of FDG uptake in relation to the timeline of COVID-19 vaccination, to prevent over-diagnosis. Although there are multiple studies recognizing COVID-19 vaccine associated lymphadenopathy [4] [5] [6] [7] , to our knowledge, to date, there is no current detailed study addressing its timeline and the degree of metabolic activity. Locally, COVID-19 vaccine associated lymphadenopathy is a commonly encountered clinical scenario. Given Canada's unique situation currently, having one of the highest rates of vaccination worldwide especially with mRNA vaccines, we aim to conduct a retrospective chart review to address this gap in knowledge, and to help guide clinical management. The objective of the study was to assess timeline and degree of 18-FDG avidity axillary lymph node in patients post COVID-19 vaccination. This is a retrospective single-center study, approved by the local Research Ethics Board. All adult patients who underwent an 18-FDG PET/CT study from May 13 th to July 8 th , 2021, with a history of COVID-19 vaccination identified on patient pre-study questionnaire were also included in the study. Basic demographic information including age and sex, as well as prior oncologic history was recorded. In addition, the date of administration, type of COVID-19 vaccine, vaccination site, and number of COVID-19 vaccine doses received (first versus second), were recorded using the data provided from the patients' electronic medical records. Other basic demographic information including age, sex and type of malignancy was also recorded. Patients with unknown vaccination date or type, and patients who had vaccines not yet approved in Canada were excluded. The presence of extensive FDG-avid metastatic lymphadenopathy, or suspected FDG-avid axillary nodal metastatic disease were the two other criteria for exclusion. For each patient, PET/CT images were re-evaluated on a HERMES workstation by one of the two board-certified Nuclear Medicine physicians, each with more than 5 years of experience. The most intense ipsilateral axillary lymph node against background was first identified visually, with its maximum standard uptake value (SUV max ) recorded. This lymph node was measured on the low dose transaxial CT images in the maximal short dimension and recorded in millimetres. Liver SUV max was also measured as an internal reference. The patients were divided in two groups for comparison purposes: (1) ≥ 1 FDG avid lymph node and (2) absence of FDG avid lymph node. The avidity of the lymph nodes (SUV max ) was then correlated with the time post-injection (0 to 2, 3 to 4 and greater than 5 weeks). The effects of the different vaccines were also evaluated. Statistical analysis was performed using IBM SPSS platform. Standard errors were reported in 95 percent confidence interval (CI) unless stated otherwise. Averages were compared using two-tailed student t-test. Ratios were compared using the twoproportions z-test. P-values less than 0.05 were considered statistically significant. In total, 202 patients, the mean age of 66.9 ± 1.9 and male to female ratio of In total, 126 patients (62.4%) had one or more FDG avid axillary lymph nodes. The mean age was 63.4 ± 2.4 years old, with a male to female ratio of 1:1.1. When present, most patients had two or more FDG avid axillary lymph nodes. The mean SUV max value was 2.5 ± 0.3 (range: 1.0 -9.2). The mean size of the most hypermetabolic lymph node was 6.2 ± 0.4 mm in the short axis. The ipsilateral axillary lymphadenopathy was the most FDG-avid in the first two weeks post vaccination, with a mean SUV max value of 3.5 ± 0.6. There was a significant reduction in SUV max value two to four weeks post injection, with a mean SUV max value of 2.4 ± 0.5 (p < 0.01, Table 1 ). There was a further decrease in SUV max value beyond the fifth week (SUV max = 1.7 ± 0.2, p < 0.01, Table 1 and Figure 2 ). In term of lymph node size, there was an apparent decrease of nodal size over time, from 6.6 ± 0.6 mm in the short axis in the first two weeks, to 5.8 ± 0.8 mm beyond the fifth week (p = 0.06, Table 1 ). This subtle difference did not reach statistical significance. There were no statistical differences in mean patient age, prevalence of primary disease, but a higher ratio of male patients was noted for the weeks 3-4 group. No FDG avid ipsilateral lymph node could be identified in 76 (37.6%) patients. These patients were statistically significantly older than the FDG avid group at 72.6 ± 2.6 years (p < 0.001, Table 1 ). The average number of days post vaccination was 38.0 ± 6.0 days, significantly longer than the average number of days post vaccination for the FDG-avid group, 25.4 ± 3.5 days (p < 0.001). Patients with non-FDG-avid lymph nodes were similarly subcategorized by weeks post-injection. The proportion of non-FDG-avid patients tended to increase with time post vaccination from 9.4% in the first four weeks, to 21.3% beyond the fifth week ( Table 1) . There was no statistically significant difference between the three groups, in term of patient's age and sex ratio. The top three most encountered malignancies in all three groups remained the same. Between the two patient groups who received either one of the two mRNA vaccines, there was no statistically significant difference in basic demographics ( Table 2 ). In terms of the PET/CT measurements, there was no statistically significant differences in SUV max measurements or nodal size between the two groups. There is a statistically significant difference in SUV max value in patients who received one or both doses of the mRNA vaccine. The average SUV max value in patients who received the first dose was 2.1 ± 0.3, versus an average SUV max value of 3.0 ± 0.4 in patients who received both doses, although this is confounded by the fact that the PET/CT studies are done earlier in the second group (34.5 ± 4.9 days, versus 15.2 ± 3.2 days). There is no statistically significant difference in nodal size in these two groups (5.7 ± 0.5 mm versus 6.6 ± 0.6 mm). The typical FDG uptake in the axillary lymph nodes post COVID-19 vaccination was mild to moderate in our study ( Figure 3B and C) . However, there were notable exceptions. In a patient with biopsy-proven lung cancer in the right middle lobe (SUV max =12.5), there were no other abnormal findings except two hypermetabolic lymph nodes in the left axilla (index node 0.9 x 1.1 cm, SUV max =13.1). The patient was 9 days post vaccination with Moderna vaccine in the left deltoid ( Figure 3A) . The case was discussed at our local thorax tumor board and the lymphatic activity was considered to be vaccine-related. Vaccine-associated lymphadenopathy is a well-established clinical scenario. In the published COVID-19 vaccine clinical trial data, axillary swelling or tenderness occurs in 10.1% and 14.2% of patients after first and second doses in receipts of Moderna vaccine [8] . In the Pfizer-BioNTech cohort, the incidence of possible vaccine related lymphadenopathy is reported to be 0.3% in all participants, slightly more common in the younger age group, age 16-55, at 0.5% [9] . Our data suggests that vaccine-associated lymph node inflammation is a more common clinical entity than what has been reported previously; 62.4% of the patients with a history of COVID-19 vaccination demonstrated at least one FDG-avid lymph node. The discrepancy between the clinical findings and our imaging findings may suggest the activity may be physiologic. Alternatively, if inflammation is present, it is most likely subclinical and low grade. Regarding the time course, we found that the FDG activity was the most intense in the first two weeks. The activity decreases and gradually resolves over time, which suggests that it is likely transient. From our data, this activity likely returns to background level 5 to 6 weeks post vaccination. This could be considered as a reasonable time point for follow up in case of any diagnostic uncertainty, such as in the special case presented above. There is an apparent further downward trend in axillary nodal metabolic activity beyond the end of the fourth week although it might not be statistically significant. This could serve as a starting point for future research, by recruiting more patients and improving statistics. In term of patient's age, we found that younger vaccinated patients were more likely to develop FDG-avid axillary lymph node, which mirrors the clinical findings published in the Pfizer-BioNTech vaccine trial [9] . Low grade axillary nodal FDG activity may simply reflect increased physiologic activity post vaccination, rather than true inflammation. Our data also suggests that there is no set size criterion to predict metabolic activity. There are several limitations in the study. Firstly, as the axillary lymph nodes are Other, rarer malignancies encountered not presented in this chart include adrenocortical carcinoma, sarcoma, gastroenteropancreatic neuroendocrine neoplasms, germ cell tumors, and ovarian cancer, as well as malignancy of unknown origin. Table 1 : Demographic and imaging characteristics of patients with ≥ 1 FDG-avid lymph node over time post-vaccination. When patients with at least one FDG-avid lymph node is subcategorized in order of time to the most recent vaccination, an apparent trend start to emerge. Although the basic demographic information stays approximately the same between the subgroups, SUV max value of the most avid ipsilateral lymph node diminish significantly over time, with the highest value seen in the first two weeks (p < 0.05). Lymph node size (mm) 6.3 ± 0.5 5.9 ± 0.7 COVID-19) Dashboard. World Health Organization website COVID-19 vaccination in Canada Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management COVID-19 vaccine-related lymph node activation -patterns of uptake on PET-CT Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine The most intense axillary lymph node is barely perceivable on the MIP image, measuring 7 mm in the short axis with a SUV max of 2.7. Incidental benign compression fracture in the midthoracic spine is also noted. C) In this 59-year-old male with primary adenocarcinoma in the left perihilar region